Abstract
Considering the difficult procedure of obtaining consent, consent-free health data reuse is believed to be one major contributor towards the creation of thriving health innovation ecosystem. While classic researchers are supported by the GDPR to reuse health data without consent, the innovator's situation remains unclear, and this uncertainty continues to exist upon the introduction of the EHDS. To shed light on grey areas, positions of GDPR and EHDS on the ability of innovators for consent-free health data reuse were assessed. The study concludes that, while academicians are able to reuse health data without consent, a private company's ability has been impeded by individual member states' deviations from Article 9(2) GDPR. Furthermore, in contracts to EHDS (2022) which appeared in favour of innovators through the elimination of consent mechanism, EHDS (2024) with the inclusion of opt-out mechanism, and exclusion of private sector bodies from the Article 35(f), has negatively affected private companies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
